Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (29683)	12/16/1999 10:02:00 AM
From: RXGOLF	Read Replies (1) \| Respond to of 32384

<<I don't think that there was anything new in the JNCI article. Just used the rat data and presented in clinical terms. However, JNCI is read by clinicians and article could cause more off label use in a couple of months, especially in advanced breast cancer patients who have failed Tamoxifen treatment.>> It my understanding that many progressive oncologist rely much more on clinical outcomes than they do of FDA approval. They have patients failing everyday using approved drugs, and they want to give them a chance with something.